Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering involving the sale of 2,661,600 shares of its common stock at $1.315 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,661,600 shares of common stock at an exercise price of $1.19 per share. The warrants will be immediately exercisable and will expire five years from the date the resale registration statement becomes effective. The offering is expected to close on or about December 16, 2025, subject to customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-25-002348), on December 16, 2025, and is solely responsible for the information contained therein.